Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

DSpace Repository

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Author: Kremsner, Peter G.; Ahuad Guerrero, Rodolfo Andres; Arana-Arri, Eunate; Aroca Martinez, Gustavo Jose; Bonten, Marc; Chandler, Reynaldo; Corral, Gonzalo; Louis De Block, Eddie Jan; Ecker, Lucie; Justin Gabor, Julian; Garcia Lopez, Carlos Alberto; Gonzales, Lucy; Granados Gonzalez, Maria Angelica; Gorini, Nestor; Grobusch, Martin P.; Hrabar, Adrian D.; Junker, Helga; Kimura, Alan; Lanata, Claudio F.; Lehmann, Clara; Leroux-Roels, Isabel; Mann, Philipp; Fernando Martinez-Resendez, Michel; Ochoa, Theresa J.; Alberto Poy, Carlos; Reyes Fentanes, Maria Jose; Rivera Mejia, Luis Maria; Ruiz Herrera, Vida Veronica; Saez-Llorens, Xavier; Schoenborn-Kellenberger, Oliver; Schunk, Mirjam; Sierra Garcia, Alexandra; Vergara, Itziar; Verstraeten, Thomas; Vico, Marisa; Oostvogels, Lidia
Tübinger Autor(en):
Kremsner, Peter
Gabor, Julian Justin
Grobusch, Martin
Published in: Lancet Infectious Diseases (2022), Bd. 22, H. 3, S. 329-340
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: https://doi.org/10.1016/S1473-3099(21)00677-0
ISSN: 1473-3099
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)